Cubist Systematic Strategies LLC Sells 114,997 Shares of Zoetis Inc. $ZTS

Key Points

• Cubist Systematic Strategies LLC significantly reduced its stake in Zoetis Inc. by 72.5%, holding a value of approximately $7.20 million in the company after selling 114,997 shares.
• Zoetis reported strong quarterly earnings with an EPS of $1.76, exceeding analysts' expectations, and a revenue increase of 4.2% year-over-year to $2.46 billion.
• Analysts show mixed sentiment towards Zoetis, with some downgrading ratings while others maintain a "Moderate Buy" consensus, indicating a current average price target of $202.43.

Cubist Systematic Strategies LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 72.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,698 shares of the company's stock after selling 114,997 shares during the quarter. Cubist Systematic Strategies LLC's holdings in Zoetis were worth $7,195,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ZTS. Brighton Jones LLC increased its stake in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in Zoetis in the 4th quarter valued at about $308,000. Aptus Capital Advisors LLC increased its stake in Zoetis by 46.6% in the 4th quarter. Aptus Capital Advisors LLC now owns 6,643 shares of the company's stock valued at $1,082,000 after buying an additional 2,111 shares during the last quarter. Captrust Financial Advisors increased its stake in Zoetis by 23.0% in the 4th quarter. Captrust Financial Advisors now owns 98,701 shares of the company's stock valued at $16,081,000 after buying an additional 18,476 shares during the last quarter. Finally, Bridgefront Capital LLC purchased a new stake in Zoetis in the 4th quarter valued at about $785,000. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Zoetis stock traded down $0.55 during mid-day trading on Monday, reaching $152.77. The company's stock had a trading volume of 446,232 shares, compared to its average volume of 3,027,536. The firm's fifty day moving average price is $153.16 and its two-hundred day moving average price is $157.73. The company has a market capitalization of $67.70 billion, a P/E ratio of 26.29, a PEG ratio of 2.46 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on ZTS. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, Zoetis presently has an average rating of "Moderate Buy" and an average target price of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.